Clinical Prior Authorization for Oxbryta in Traditional Medicaid Begins Sept. 8, 2020

Clinical Prior Authorization for Oxbryta in Traditional Medicaid Begins Sept. 8, 2020

VDP will implement the clinical prior authorization criteria for Oxbryta (voxelotor) for traditional Medicaid on Sept. 8. The Texas Drug Utilization Review Board approved Oxbryta as part of the Sickle Cell Disease Agents criteria (PDF) at its Jan. 2020 meeting. This prior authorization is optional for Medicaid managed care. The Pharmacy Clinical Prior Authorization Assistance Chart (PDF) shows the prior authorization each MCO uses and how those authorizations relate to traditional Medicaid claim processing. This chart is updated quarterly and available on the VDP website. For FirstCare clinical edits please click here.

Send to a Friend

* Required field

Captcha The math problem above is intended to reduce spam.